2021 Global Biopharma R&D Productivity And Growth Ranking

Including First Ever Small- To Mid-Size Pharma Ranking

A turbulent 2021: we are now in our eighth year of reviewing R&D productivity and corporate growth of the top 30 biopharma companies. While 2021 was dominated by the COVID-19 pandemic, biopharma as a whole had a good but not great year.

chess pieces
• Source: Alamy

With 50 in 2021, the number of FDA approvals has stabilized at a high level in recent years and compares favorably to an average of 43 approvals over the last 10 years. The Dow Pharma index went up but has lagged behind the S&P 500 whereas biotech stocks took a beating in 2021, especially the small caps. (By the end of 2021 XBI was down ca. 20% compared to the beginning of the year and down by 33% versus its peak in February 2021, a trend that has continued in early 2022.)

In our survey the R&D productivity of the top 30 biopharma companies has remained relatively stable since 2018. The largest...

More from Growth

More from In Vivo